StoxAnupam Rasayan India vs Jubilant Ingrevia: share price & financials comparison
NSE: ANURAS vs JUBLINGREA · Chemicals · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Anupam Rasayan India vs Jubilant Ingrevia at a glance
Anupam Rasayan India (ANURAS) has a market capitalisation of ₹14,807 Cr, against ₹9,325 Cr for Jubilant Ingrevia (JUBLINGREA). Over the past year Anupam Rasayan India has returned +21.0%, compared with -14.3% for Jubilant Ingrevia. On valuation, Jubilant Ingrevia trades at a lower P/E of 26.6 versus 82.1. Jubilant Ingrevia earns a higher return on equity (10.6% vs 3.6%). Anupam Rasayan India comes out ahead on momentum and technicals. Jubilant Ingrevia comes out ahead on size, valuation, profitability, growth and financial health. Across the scored metrics below, Anupam Rasayan India leads on 7 and Jubilant Ingrevia on 10. On StoxGud's 10-point checklist, Anupam Rasayan India scores 5/10 and Jubilant Ingrevia scores 4/10.
| Metric | Anupam Rasayan India | Jubilant Ingrevia |
|---|---|---|
| Size | ||
| Market cap | ₹14,807 Cr | ₹9,325 Cr |
| Revenue (latest FY) | ₹2,365 Cr | ₹4,388 Cr |
| Net profit (latest FY) | ₹170 Cr | ₹278 Cr |
| Valuation | ||
| P/E | 82.1 | 26.6 |
| P/B | 2.93 | 2.81 |
| Dividend yield | 0.10% | 0.85% |
| Profitability | ||
| Return on equity | 3.6% | 10.6% |
| Net profit margin | 6.9% | 7.1% |
| Operating margin | 23.5% | 14.2% |
| Growth | ||
| Revenue growth (YoY) | +10.2% | +24.4% |
| Net profit growth (YoY) | +12.7% | +60.4% |
| Revenue CAGR (multi-year) | +23.9% | +45.0% |
| Financial health | ||
| Debt to equity | 0.49 | 0.27 |
| Momentum | ||
| 1-month return | +11.6% | -5.7% |
| 1-year return | +21.0% | -14.3% |
| 3-year CAGR | +12.3% | +12.1% |
| 5-year CAGR | +9.5% | -1.6% |
| Distance from 52W high | -5.5% | -22.5% |
| Technicals | ||
| RSI (14) | 83 | 47 |
| Price vs 200-day avg | +3.9% | -9.7% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Anupam Rasayan India | Jubilant Ingrevia |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✓ |
| Score | 5/10 | 4/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Anupam Rasayan India or Jubilant Ingrevia?
Anupam Rasayan India has a market cap of ₹14,807 Cr and Jubilant Ingrevia has a market cap of ₹9,325 Cr as of 13 Nov 2026.
Which has a lower P/E, Anupam Rasayan India or Jubilant Ingrevia?
Jubilant Ingrevia has the lower P/E: Anupam Rasayan India trades at 82.1 and Jubilant Ingrevia at 26.6.
Which gave better returns in the last year, Anupam Rasayan India or Jubilant Ingrevia?
Anupam Rasayan India did better: Anupam Rasayan India returned +21.0% and Jubilant Ingrevia returned -14.3% over one year.
What is the difference between Anupam Rasayan India and Jubilant Ingrevia?
Both are NSE-listed companies in Chemicals. Anupam Rasayan India is about 1.6 times the size of Jubilant Ingrevia by market cap. In the latest financial year Anupam Rasayan India reported revenue of ₹2,365 Cr and Jubilant Ingrevia ₹4,388 Cr. Operating margin is 23.5% for Anupam Rasayan India and 14.2% for Jubilant Ingrevia. Debt to equity is 0.49 for Anupam Rasayan India and 0.27 for Jubilant Ingrevia.
Which is better, Anupam Rasayan India or Jubilant Ingrevia?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Anupam Rasayan India leads on 7 and Jubilant Ingrevia on 10. Anupam Rasayan India is ahead on momentum and technicals. Jubilant Ingrevia is ahead on size, valuation, profitability, growth and financial health. On StoxGud's rules-based checklist Anupam Rasayan India scores 5/10 and Jubilant Ingrevia scores 4/10. This is information, not advice: consult a SEBI-registered adviser before investing.